LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Bionano Genomics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERBNGO
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / BNGO COVERAGE

What’s moving Bionano Genomics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2026 Earnings Call Transcript

Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2026 Earnings Call Transcript

Investors are testing whether Bionano Genomics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2025 Earnings Call Transcript

Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2025 Earnings Call Transcript

Investors are testing whether Bionano Genomics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Bionano Genomics, Inc. Announces 1-for-60 Reverse Stock Split Effective January 24, 2025

Bionano Genomics, Inc. Announces 1-for-60 Reverse Stock Split Effective January 24, 2025

Investors are testing whether Bionano Genomics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Bionano Genomics, Inc. Announces Settlement Agreement and Amendment to Convertible Debentures Enhancing Capital Structure and Liquidity

Bionano Genomics, Inc. Announces Settlement Agreement and Amendment to Convertible Debentures Enhancing Capital Structure and Liquidity

The story matters when it changes Bionano Genomics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript

Investors are testing whether Bionano Genomics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest BNGO filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-13 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-23 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-24 · Period 2026-06-24SEC ↗8-KMaterial company eventFiled 2026-06-05 · Period 2026-06-02SEC ↗8-KMaterial company eventFiled 2026-05-28 · Period 2026-05-28SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-02 · Period 2026-04-01SEC ↗3Official SEC filingFiled 2026-07-30 · Period 2026-07-20SEC ↗
EARNINGS / QUARTERLY TRACKER

Bionano Genomics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.